Company Overview - BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging [3] - The company's lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor aimed at treating cardiovascular risk and retinal diseases [3] - BioAge is also developing long-acting injectable and oral small molecule APJ agonists for obesity, alongside additional preclinical programs that leverage insights from human longevity data [3] Upcoming Events - BioAge will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026 [1] - CEO Kristen Fortney and CFO Dov Goldstein will participate in a fireside chat and one-on-one meetings during the conference [2] - A live webcast of the presentation will be available, with replays accessible on the company's investor website for 30 days post-event [2] Clinical Development - A Phase 1 SAD/MAD trial of BGE-102 is currently underway, with topline data, including additional MAD cohorts, expected in the first half of 2026 [3]

Core Insights - BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic products for metabolic diseases by targeting human aging biology [1][3] - The company will present at the Piper Sandler 37th Annual Healthcare Conference in New York from December 2-4, 2025 [1][2] - Key executives, including CEO Kristen Fortney and CFO Dov Goldstein, will participate in a fireside chat and one-on-one meetings during the conference [2] Company Overview - BioAge's lead product candidate, BGE-102, is an orally available small-molecule NLRP3 inhibitor aimed at treating obesity and cardiovascular risk factors [3] - A Phase 1 SAD/MAD trial for BGE-102 is currently underway, with initial SAD data expected by the end of the year [3] - The company is also developing long-acting injectable and oral small molecule APJ agonists for obesity, alongside additional preclinical programs targeting metabolic aging pathways [3]